Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Home Diagnostics, Cellnovo announce strategic business deal

Building on a shared vision to simplify diabetes management worldwide, Cellnovo, a London-based medical device company, and Home Diagnostics, Inc., a leader in diabetes products, today announced a strategic alliance that involves integrating technologies and developing distribution opportunities for Cellnovo's insulin patch pumps.

6 May 2010

Novocell is now ViaCyte

Novocell, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today the Company's shareholders and Board of Directors approved a name change to ViaCyte, Inc.

6 May 2010

Single night of partial sleep deprivation induces insulin resistance in healthy people

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), just one night of short sleep duration can induce insulin resistance, a component of type 2 diabetes.

5 May 2010

Diets rich in whole grain reduce risk of obesity and other diseases related to metabolic syndrome

Evidence from observational studies indicates that diets rich in whole grain reduce risk of obesity and other diseases related to the metabolic syndrome e.g. type 2 diabetes and cardio-vascular disease. The mechanisms involved are only partially elucidated. Work within HEALTHGRAIN has revealed novel insights regarding some potential mechanisms.

5 May 2010

HbA1c can be deceptive in African American children with diabetes: Study

Researchers at LSU Health Sciences Center New Orleans and Children's Hospital of New Orleans have found that there is a major difference in the hemoglobin A1c response to blood glucose between African-American and Caucasian children with diabetes. HbA1c is the main test used to monitor diabetes and guide treatment decisions.

5 May 2010

Enzyme technology developed to improve quality, safety and nutritional attributes of oat based foods

Oats is a highly nutritious cereal, which can be tolerated by large number of celiac patients. A range of commercial oat flours as well as specific oat flours produced from single varieties have been evaluated for their suitability for bread-baking. Enzyme technology, bioprocessing as well as high-pressure processing technology have been successfully applied to improve the quality, safety and nutritional attributes of oat based foods.

5 May 2010

Animal study shows insulin prevents artery damage

Long suspected of worsening artery damage in patients with diabetes, insulin instead protects blood vessels, a new study by Joslin Diabetes Center scientists indicates.

5 May 2010

Osiris Therapeutics' Prochymal granted FDA Orphan Drug Designation

Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.

5 May 2010

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

Forest Laboratories, Inc. today presented data from a Phase IV study evaluating the effects of Bystolic (nebivolol) tablets in Hispanic patients with hypertension at the 2010 annual scientific meeting of the American Society of Hypertension.

4 May 2010

NIH awards Hutchinson Center $10.24M for research of breast cancer disparities in Hispanic women

The National Institutes of Health has awarded $10.24 million to Fred Hutchinson Cancer Research Center to lead a five-year study that aims to understand and prevent breast cancer disparities in Hispanic women.

4 May 2010

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Raptor Pharmaceutical Corp., announced positive Phase 2a clinical trial results from its pilot study of delayed-release cysteamine bitartrate in 11 adolescent patients with non-alcoholic steatohepatitis, a progressive form of liver disease believed to affect 5% to 11% of the U.S. population. The results were presented at the Digestive Disease Week 2010 conference in New Orleans, LA on May 2, 2010.

3 May 2010

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

The Scripps Research Institute has been awarded a $1.3 million grant by the National Institutes of Health (NIH) to develop a series of tests at its Florida campus to help explore the potential of a protein that has emerged as a highly attractive target for the treatment of obesity and Type 2 diabetes.

3 May 2010

Pfizer to maintain top spot in prescription sales through mergers and acquisitions

The rheumatoid arthritis treatment Humira will replace Lipitor as the world's biggest-selling drug in 2016, but a familiar name, Pfizer, will still be the biggest seller of medicines after the patent cliff according to the World Preview 2016 report published today by EvaluatePharma, the premier provider of pharma and biotech analysis.

3 May 2010

Majority of patients who appear healthy may be at risk for cardiovascular disease

Three separate studies announced today at the American Society of Hypertension Inc.'s 25th Annual Scientific Meeting and Exposition (ASH 2010) examined the cardiovascular consequences of relatively healthy patients - those who were asymptomatic and not classified as hypertensive or diabetic - and found that many patients who appear healthy may still be at risk for cardiovascular disease.

3 May 2010

Vitamin E effective in treating NASH: Study

Vitamin E has been shown effective in treating nonalcoholic steatohepatitis, an obesity-associated chronic liver disease that can lead to cirrhosis, liver cancer, and death. NASH also is related to or a part of type 2 diabetes, lipid disorders and cardiovascular disease.

3 May 2010

MicroCHIPS receives 2010 Edison Best New Product Award for Illume System

MicroCHIPS, Inc., a developer of intelligent implant systems, today announced that it has received a 2010 Edison Best New Product Award for its Illume product. The product was awarded Gold in the Science and Medical Category, recognizing the benefit that it will bring to millions of people with diabetes who must manage their blood sugar intensively to stay healthy.

30 Apr 2010

MannKind reports first-quarter net loss of $44.7 million applicable to common stockholders

MannKind Corporation today reported financial results for the first quarter ended March 31, 2010.

30 Apr 2010

Generex Biotechnology receives U.S. patent for method of administering insulin to the buccal region

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has received a new patent in the United States.

30 Apr 2010

West Pharmaceutical Services reports 13.3% increase in first-quarter consolidated sales

West Pharmaceutical Services, Inc. today announced its results for the first quarter of 2010.

30 Apr 2010

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that results from a pre-clinical study showed significant improvement in the delivery and half life of Å6, a proprietary peptide treatment for ovarian cancer currently in Phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT® enabled the dose of Å6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.

29 Apr 2010

Insulin News and Research

Further Reading

Home Diagnostics, Cellnovo announce strategic business deal

Novocell is now ViaCyte

Single night of partial sleep deprivation induces insulin resistance in healthy people

Diets rich in whole grain reduce risk of obesity and other diseases related to metabolic syndrome

HbA1c can be deceptive in African American children with diabetes: Study

Enzyme technology developed to improve quality, safety and nutritional attributes of oat based foods

Animal study shows insulin prevents artery damage

Osiris Therapeutics' Prochymal granted FDA Orphan Drug Designation

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

NIH awards Hutchinson Center $10.24M for research of breast cancer disparities in Hispanic women

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

Pfizer to maintain top spot in prescription sales through mergers and acquisitions

Majority of patients who appear healthy may be at risk for cardiovascular disease

Vitamin E effective in treating NASH: Study

MicroCHIPS receives 2010 Edison Best New Product Award for Illume System

MannKind reports first-quarter net loss of $44.7 million applicable to common stockholders

Generex Biotechnology receives U.S. patent for method of administering insulin to the buccal region

West Pharmaceutical Services reports 13.3% increase in first-quarter consolidated sales

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News